AIMA
REGN icon

Ables Iannone Moore & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Ables Iannone Moore & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3
Closed -$2.63K – 241
2023
Q4 		$2.63K Buy
+3
New +$2.47K ﹤0.01% 225

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ables Iannone Moore & Associates's REGN Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 3 shares — an estimated $2.63K sold.

Ables Iannone Moore & Associates first reported a position in REGN in Q4 2023 and held it in 1 quarter. The position peaked at $2.63K in Q4 2023. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 3 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $2.63K.
  • Ables Iannone Moore & Associates first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's Regeneron Pharmaceuticals position peaked at $2.63K in Q4 2023.
  • 1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.